1. Home
  2. PBMWW vs CERT Comparison

PBMWW vs CERT Comparison

Compare PBMWW & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • CERT
  • Stock Information
  • Founded
  • PBMWW N/A
  • CERT 2008
  • Country
  • PBMWW Canada
  • CERT United States
  • Employees
  • PBMWW 10
  • CERT N/A
  • Industry
  • PBMWW
  • CERT Retail: Computer Software & Peripheral Equipment
  • Sector
  • PBMWW
  • CERT Technology
  • Exchange
  • PBMWW Nasdaq
  • CERT Nasdaq
  • Market Cap
  • PBMWW N/A
  • CERT N/A
  • IPO Year
  • PBMWW N/A
  • CERT 2020
  • Fundamental
  • Price
  • PBMWW $0.02
  • CERT $11.34
  • Analyst Decision
  • PBMWW
  • CERT Buy
  • Analyst Count
  • PBMWW 0
  • CERT 8
  • Target Price
  • PBMWW N/A
  • CERT $17.79
  • AVG Volume (30 Days)
  • PBMWW N/A
  • CERT 1.6M
  • Earning Date
  • PBMWW N/A
  • CERT 11-06-2024
  • Dividend Yield
  • PBMWW N/A
  • CERT N/A
  • EPS Growth
  • PBMWW N/A
  • CERT N/A
  • EPS
  • PBMWW N/A
  • CERT N/A
  • Revenue
  • PBMWW N/A
  • CERT $363,553,000.00
  • Revenue This Year
  • PBMWW N/A
  • CERT $11.07
  • Revenue Next Year
  • PBMWW N/A
  • CERT $10.78
  • P/E Ratio
  • PBMWW N/A
  • CERT N/A
  • Revenue Growth
  • PBMWW N/A
  • CERT 3.26
  • 52 Week Low
  • PBMWW N/A
  • CERT $10.35
  • 52 Week High
  • PBMWW N/A
  • CERT $19.87
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • CERT 48.32
  • Support Level
  • PBMWW N/A
  • CERT $10.87
  • Resistance Level
  • PBMWW N/A
  • CERT $11.45
  • Average True Range (ATR)
  • PBMWW 0.00
  • CERT 0.39
  • MACD
  • PBMWW 0.00
  • CERT 0.12
  • Stochastic Oscillator
  • PBMWW 0.00
  • CERT 56.44

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: